CN102940750B - Medicine composition for treating gout - Google Patents
Medicine composition for treating gout Download PDFInfo
- Publication number
- CN102940750B CN102940750B CN201210427806.XA CN201210427806A CN102940750B CN 102940750 B CN102940750 B CN 102940750B CN 201210427806 A CN201210427806 A CN 201210427806A CN 102940750 B CN102940750 B CN 102940750B
- Authority
- CN
- China
- Prior art keywords
- extract
- ethanol
- fructus mori
- radix paeoniae
- paeoniae rubra
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 44
- 201000005569 Gout Diseases 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title abstract description 10
- 229940079593 drug Drugs 0.000 title description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 30
- 241000255789 Bombyx mori Species 0.000 claims abstract description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 95
- 229960004756 ethanol Drugs 0.000 claims description 44
- 239000007788 liquid Substances 0.000 claims description 39
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 239000000706 filtrate Substances 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 238000000605 extraction Methods 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 14
- 238000004108 freeze drying Methods 0.000 claims description 14
- 238000003828 vacuum filtration Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 11
- 238000001816 cooling Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 7
- 239000003463 adsorbent Substances 0.000 claims description 7
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 7
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 7
- 238000005325 percolation Methods 0.000 claims description 7
- 239000002798 polar solvent Substances 0.000 claims description 7
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 208000024891 symptom Diseases 0.000 abstract description 2
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- 239000012567 medical material Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 201000001431 Hyperuricemia Diseases 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000007901 soft capsule Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229960001338 colchicine Drugs 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000004044 Hypesthesia Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000034783 hypoesthesia Diseases 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010070968 Disorders of purine metabolism Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 208000026816 acute arthritis Diseases 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000850 chronic interstitial nephritis Toxicity 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicine composition for treating gout, comprising red peony root, semen arecae, mulberry and silkworm excrement. The medicine composition disclosed herein can quickly alleviate clinical symptoms of patients and has the advantages of low price and no side effect.
Description
Technical field
The present invention relates to medical art, relate to the pharmaceutical composition for the treatment of gout or rather.
Background technology
Gout is also known as hyperuricemia, and sickness rate is high, healing is difficult, recurrent exerbation, belongs to the metabolic disease that disorders of purine metabolism causes.Gout is multiple is born in middle-aged and elderly people, overweight people and brain worker, the gouty acute arthritis recurrent exerbation that its clinical characters is hyperuricemia and causes thus, tophaceous deposition, tophaceous chronic arthritis and joint deformity etc., dumb for main clinical manifestation with redness and swelling of joints, burning pain, recurrent exerbation, joint motion.Often involving kidney causes chronic interstitial nephritis and uric acid kidney stones to be formed.Increase reason according to uric acid in blood and can be divided into constitutional and the large class of Secondary cases two.The cause of disease of primary gout is caused by congenital purine metabolic disturbance, belongs to heritability.The cause of disease of secondary gout, can be caused by many reasons such as nephropathy, leukemia, medicine, foods, be apt to occur in male and menopausal woman.Gout belongs to Chinese medicine " arthromyodynia " category." treatise on blood trouble ": " gout, general numbness and hypoesthesia, limbs pain, modern name gout, Gu say arthromyodynia ".
The Western medicine being used for the treatment of gout at present mainly contains: colchicine, Phenylbutazone or crovaril, indometacin, ibuprofen (ibvprofen, ibuprofen), piroxicam (piroxicanum), naproxen (naproxen congex), ACTH and prednisone etc.But said medicine can only stablize the state of an illness mostly, gout can not be effected a radical cure; Serious side effect also can be caused to cause the infringement of hepatic and renal function; Even if Emergent therapy effectively can not recur by symptom management, and drug resistance and repellence can be produced, even there will be leukopenia, cardiac function is impaired, hepatic and renal function is impaired, stimulating intestine and stomach system, aplastic anemia, cause the complication such as diabetes.Increasing expert thinks: from the organic conception of the traditional Chinese medical science, treats with Chinese medicine integral syndrome differentiation, the good footpath of another bar for the treatment of gout of can yet be regarded as; Not only the toxic and side effects of Chinese medicine itself greatly reduces, and can reduce Western medicine dose, overcomes the huge toxic and side effects taken merely Western medicine for a long time and bring.But the Chinese patent medicine for the treatment of gout is in the market few, and curative effect lacks preferably especially, and patient still can only carry out the stable state of an illness by taking the larger Western medicine of toxic and side effects in a large number.
Summary of the invention
The object of the present invention is to provide a kind of treat gout, the pharmaceutical composition of determined curative effect.This medicine composite for curing gout is with strong points, and curative effect is better, and side effect is little, and safety is good.
To achieve these goals, technical scheme provided by the invention is:
Treat a pharmaceutical composition for gout, it is the medicament that medicinal raw material is made by Radix Paeoniae Rubra, Semen Arecae, Fructus Mori and silkworm excrement.
The weight proportion of pharmaceutical composition of the present invention medicine material used can be: Radix Paeoniae Rubra 6-18 part, Semen Arecae 3-15 part, Fructus Mori 3-15 part, silkworm excrement 2-10 part.
More preferably the proportioning of pharmaceutical composition of the present invention medicine material used is: Radix Paeoniae Rubra 9-15 part, Semen Arecae 6-12 part, Fructus Mori 6-12 part, silkworm excrement 4-8 part.
The optimum proportioning of pharmaceutical composition of the present invention medicine material used is: Radix Paeoniae Rubra 12 parts, Semen Arecae 9 parts, 9 parts, Fructus Mori, silkworm excrement 6 parts.
Each crude drug can be made the medicine of any one dosage form suitable on pharmaceutics by formulation method conveniently by the pharmaceutical composition of above-mentioned treatment gout after treatment, preferably makes granule, tablet, hard capsule, oral liquid, soft capsule, drop pill etc.
According to the needs of the various drug form of preparation, pharmaceutical composition of the present invention can adopt and can adopt but be not limited to following methods:
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 8-10 times of volume, each 1-2h, merge extractive liquid, reclaims ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 8-10 times of volume lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 8-10 times of volume lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) by above-mentioned each extract mixing, acceptable various pharmaceutical dosage form is made.
According to the needs of the various drug form of preparation, medicine of the present invention also can add suitable pharmaceutic adjuvant as filler, disintegrating agent, binding agent, lubricant, antiseptic etc. in preparation process.
The present invention's various raw medicinal materials used are the Chinese crude drug meeting country or provincial standard and specify.
Compared with prior art, the invention has the beneficial effects as follows:
The present invention treats in the pharmaceutical composition of gout, and Radix Paeoniae Rubra is bitter, and taste is micro-cool, returns Liver Channel.Clearing away heat and cooling blood, can promoting blood circulation to remove obstruction in the collateral.Shennong's Herbal: " Radix Paeoniae, bitter in the mouth is put down.Main pathogen stomachache, except arthralgia due to stagnation of blood ... " Semen Arecae bitter in the mouth, pungent, warm in nature.Parasite killing, removing food stagnancy, circulation of qi promoting, diuretic, preventing the attack (or recurrence) of malaria.Fructus Mori sweet in the mouth, acid, nourishing YIN and supplementing blood, promotes the production of body fluid and moisturizes.Silkworm excrement wind-damp dispelling, pain relieving.Above 4 taste Chinese medicine composition application, have Synergistic function, be used for the treatment of gout, determined curative effect, show through clinical research, it is better that medicine of the present invention is used for the treatment of gout curative effect, and do not find obvious side effect and untoward reaction.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in further detail.
Embodiment 1
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 12g, Semen Arecae 9g, Fructus Mori 9g, silkworm excrement 6g.
Make granule as follows: the crude drug getting described proportioning, adds suitable quantity of water respectively, adopt decocting method to extract 2 times respectively, filter, merge 2 filtrates, by each concentrated solution mix homogeneously after concentrated, dry, be distributed into bag after granulation and get final product.
Embodiment 2
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 18g, Semen Arecae 15g, Fructus Mori 15g, silkworm excrement 10g.
Make granule as follows: the crude drug getting described proportioning, add appropriate 70% ethanol respectively, adopt reflux extraction to extract 3 times respectively, filter, merge 3 filtrates, by each concentrated solution mix homogeneously after recovery ethanol also concentrates, drying, is distributed into bag and get final product after granulation.
Embodiment 3
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 9g, Semen Arecae 6g, Fructus Mori 6g, silkworm excrement 4g.
Make granule by the following method:
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 9 times of volumes, each 2h, merge extractive liquid, reclaim ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 9 times of volumes lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 9 times of volumes lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) above-mentioned each extract mix homogeneously is got, dry, be distributed into bag after granulation, make granule.
Embodiment 4
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 6g, Semen Arecae 3g, Fructus Mori 3g, silkworm excrement 2g.
Be prepared into soft capsule by the following method:
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 8 times of volumes, each 1.5h, merge extractive liquid, reclaim ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) by above-mentioned each extract mixing, add vegetable oil 25g, mixing, makes capsule casing material with gelatin, is pressed into soft capsule.
Embodiment 5
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 15g, Semen Arecae 12g, Fructus Mori 12g, silkworm excrement 8g.
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 10 times of volumes, each 1h, merge extractive liquid, reclaim ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 10 times of volumes lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) above-mentioned each extract is dissolved in 1000mL water for injection, adopts existing preparation of injection, obtained injectable powder.
Embodiment 6
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 12g, Semen Arecae 6g, Fructus Mori 6g, silkworm excrement 4g.
Aforementioned pharmaceutical compositions is prepared into capsule:
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 10 times of volumes, each 1h, merge extractive liquid, reclaim ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 9 times of volumes lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) above-mentioned each extract is mixed homogeneously with starch 100g, adopt capsules preparation technique, obtained capsule.
Embodiment 7
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 9g, Semen Arecae 12g, Fructus Mori 3g, silkworm excrement 2g.
Above-mentioned medicinal raw material is prepared into tablet:
(1) get Radix Paeoniae Rubra medical material, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by this water elution liquid; Use the high concentration ethanol eluting of 80% again, collect this high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract.
(2) get Semen Arecae material, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 8 times of volumes, each 2h, merge extractive liquid, reclaim ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times.Filter after this carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume and obtain Semen Arecae extract.
(3) get Fructus Mori medical material, rub, to add at 85% ethanol 75 DEG C of 10 times of volumes lixiviate 2 times, each 1.5h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(4) get silkworm excrement medical material, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 6h.Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, obtains Fructus Mori extract after concentrated solution lyophilization.
(5) by above-mentioned each extract mix homogeneously, dry, tabletting and get final product after granulating.
Embodiment 8
The pharmaceutical composition of the treatment gout that the present embodiment is enumerated, is made up of the medicinal raw material of following weight:
Radix Paeoniae Rubra 18g, Semen Arecae 12g, Fructus Mori 3g, silkworm excrement 2g.
Make capsule as follows: the crude drug getting described proportioning, mixes, and adds suitable quantity of water, adopt decocting method to extract 2 times, filter, merge 2 filtrates, concentrated, dry, load in hungry area softgel shell after granulating and get final product.
The various embodiments described above medicine, also can according to the formulation method of other routine, by each crude drug of corresponding weight proportion after the method process such as other Isolation and purification, make the medicine of other dosage form again, as: granule, tablet, hard capsule, oral liquid, soft capsule, drop pill, water pill, honeyed pill etc.
In addition, according to the needs of the various drug form of preparation, the various embodiments described above medicine also can add suitable pharmaceutic adjuvant as magnesium stearate, starch, dextrin, sucrose, microcrystalline Cellulose, hydroxypropyl emthylcellulose, vegetable oil, lecithin, Polyethylene Glycol, propylene glycol, ethyl hydroxybenzoate etc. in preparation process.
Test example
In order to the efficacy and saferry of proved invention medicine, inventors performed pharmacodynamics and toxicity test investigation.The research method adopted and result of the test as follows:
(1) pharmacodynamics test research
1, test material
(1), medicine and reagent:
The extract that medicine of the present invention is made for crude drug weight proportion and method according to embodiment 4.
Colchicine is Yunnan Plant Pharmaceutical Industry Co., Ltd.'s product.
(2), animal: Kunming mouse, SD rat, provided by Sichuan institute of antibiotics Experimental Animal Center.
2, test method and result
(1) on the impact of hyperuricemia Mouse Blood uric acid level
Get Kunming mouse 60, male and female are all used, body weight 18 ~ 22g, be divided into dosage group (8g raw medicinal herbs/kg), medicine high dose group of the present invention (16g raw medicinal herbs/kg), positive controls in normal saline group, medicine low dose group of the present invention (4g raw medicinal herbs/kg), medicine of the present invention at random, gavage normal saline, medicine of the present invention and colchicine respectively, every day 1 time, continuous 4d.After last administration 1h, except normal saline group, all the other each treated animal Intraperitoneal injection of hypoxanthine 1mg/kg cause mice hyperuricemia, the capacity blank liquid such as normal saline group injection.0.5h after injection, each treated animal is plucked eyeball and is got blood, the centrifugal 15min of 3000r/min, gets serum and surveys Level of Serum Uric Acid.
Table 1 is on the impact of hyperuricemia Mouse Blood uric acid level
Note: compare with model group: * * P<0.01
As can be seen from the table, the high, medium and low dosage of medicine of the present invention is respectively organized and all can be reduced Mouse Blood uric acid level, and comparing with model group has significant difference.
Claims (1)
1. treat a pharmaceutical composition for gout, it is characterized in that: it is the medicament be made up of the medicinal raw material of following weight parts proportioning: Radix Paeoniae Rubra 6 parts, Semen Arecae 3 parts, Fructus Mori 3 parts, silkworm excrement 2 parts; Described pharmaceutical composition is obtained by following methods:
(1) get Radix Paeoniae Rubra, use water percolation, collect percolate, by percolate by macroporous adsorbent resin, first wash with water, removing is dissolved in the impurity of polar solvent, is discarded by water elution liquid; Use the high concentration ethanol eluting of 80% again, collect high concentration ethanol eluent, by dry for the eluent reclaimed after ethanol, obtain Radix Paeoniae Rubra extract;
(2) get Semen Arecae, pulverize, add the dehydrated alcohol reflux, extract, 3 times of 8 times of volumes, each 1.5h, merge extractive liquid, reclaims ethanol, concentrated solution adds strong aqua ammonia after placing cooling and is adjusted to pH=10, adds 1/10 volume ratio carbon tetrachloride and stirs extraction 3 times, obtain carbon tetrachloride extraction liquid; Filter after described carbon tetrachloride extraction liquid anhydrous sodium sulfate drying, collect filtrate reduced in volume, obtain Semen Arecae extract;
(3) get Fructus Mori, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 1.5h; Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, after concentrated solution lyophilization, obtains Fructus Mori extract;
(4) get silkworm excrement, rub, to add at 85% ethanol 75 DEG C of 8 times of volumes lixiviate 2 times, each 6h; Merge extractive liquid, vacuum filtration removes the gred, and filtrate is concentrated under 40 DEG C of conditions by rotary evaporator, after concentrated solution lyophilization, obtains silkworm excrement extract;
(5) Radix Paeoniae Rubra extract, Semen Arecae extract, Fructus Mori extract and the silkworm excrement extract mixing obtained respectively step (1)-(4), makes acceptable various pharmaceutical dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210427806.XA CN102940750B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating gout |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210427806.XA CN102940750B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating gout |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940750A CN102940750A (en) | 2013-02-27 |
| CN102940750B true CN102940750B (en) | 2015-02-25 |
Family
ID=47723810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210427806.XA Expired - Fee Related CN102940750B (en) | 2012-10-31 | 2012-10-31 | Medicine composition for treating gout |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940750B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104435567A (en) * | 2014-11-07 | 2015-03-25 | 成都华熹科技有限公司 | Traditional Chinese medicinal composition containing gynostemma pentaphyllum for treating gout |
| CN104337889B (en) * | 2014-11-07 | 2016-07-13 | 成都华熹科技有限公司 | A kind of Chinese medicine composition of the treatment gout containing Lumbricus |
| CN108379419A (en) * | 2018-04-27 | 2018-08-10 | 湖南口味王集团有限责任公司 | A kind of composition for reducing uric acid |
-
2012
- 2012-10-31 CN CN201210427806.XA patent/CN102940750B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940750A (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102940695B (en) | Medicine composition for treating gout | |
| CN1947757B (en) | Leave of glutinous rehmannia extractive, its preparation method and use, medicines prepared with said extractives | |
| CN102940750B (en) | Medicine composition for treating gout | |
| CN104288594B (en) | A kind ofly treat Chinese medicine preparation of chronic kidney disease syndrome of deficiency of both qi and yin and preparation method thereof | |
| CN102940709B (en) | Medicine composition for treating gout | |
| CN102657736B (en) | Medicament composition for treating rheumatoid arthritis and preparation method of medicament composition | |
| CN102940850B (en) | Medicine composition for treating gout | |
| CN106266949A (en) | A kind of compound Chinese medicinal preparation and its preparation method and application | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN104337909B (en) | A kind of Chinese medicine composition of the treatment gout containing Aspongopus | |
| CN104435079A (en) | Traditional Chinese medicinal composition for treating gout | |
| CN104095940A (en) | Traditional Chinese medicine composition for treating gout | |
| CN104337898B (en) | A kind of Chinese medicine composition of the treatment gout containing Semen Pruni | |
| CN102940656B (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN102512596A (en) | Traditional Chinese medicine for treating allergic purpura | |
| CN102670831B (en) | Medicinal composition for treating dermatomyositis and preparation method thereof | |
| CN102940740A (en) | Medicament for treating lithiasis and preparation method thereof | |
| CN104435149A (en) | Traditional Chinese medicine composition containing kadsura pepper stem for treating gout | |
| CN104398564A (en) | Tripterygium wilfordii containing Chinese medicinal composition for treatment of gout | |
| CN102210759B (en) | Application of Chinese medicinal component in preparation of nitric oxide donor medicament | |
| CN104436017A (en) | Traditional Chinese medicine composition containing caulis akebiae for treating gout | |
| CN106902330B (en) | Traditional Chinese medicine preparation for treating rheumatic arthritis and rheumatalgia and preparation method and application thereof | |
| CN103735671B (en) | A kind of medicine for the treatment of gout |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150225 |